ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Key facts
- Where
- Barrie, London, Peterborough, Surrey, and Waterloo, CanadaSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT07783542, who can take part
Where in Canada
- Barrie, OntarioHospital not named in the registryContact: Oruka Investigative SiteTaking people
- London, OntarioHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Peterborough, OntarioHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Surrey, British ColumbiaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Waterloo, OntarioHospital not named in the registryContact: Oruka Investigative SiteTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Oruka Therapeutics, Inc.
- Trial code
- NCT07783542
- Record updated
- 29 October 2026
- Original description
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.Read full original descriptionShow less
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Inclusion: Has signs and symptoms of HS for at least 6 months; Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III; Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic antibiotics for HS, demonstrated intolerance to systemic antibiotics for HS, or has a contraindication to systemic antibiotics for HS.
Exclusion: Presence of any other active skin disease or condition that may interfere with the assessment of HS; Diagnosis or suspected diagnosis of autoimmune diseases or inflammatory conditions other than HS.